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Deﬁning myocardial tissue abnormalities in
end-stage renal failure with cardiac magnetic
resonance imaging using native T1 mapping
Elaine Rutherford1,2, Mohammed A. Talle1, Kenneth Mangion1, Elizabeth Bell1, Samuli M. Rauhalammi1,
Giles Roditi1, Christie McComb1, Aleksandra Radjenovic1, Paul Welsh1, Rosemary Woodward1,
Allan D. Struthers2, Alan G. Jardine1, Rajan K. Patel1, Colin Berry1 and Patrick B. Mark1
1Institute of Cardiovascular and Medical Sciences, BHF Glasgow Cardiovascular Research Centre, University of Glasgow, Scotland, UK; and
2University of Dundee, Division of Cardiovascular & Diabetes Medicine, Dundee, Scotland, UK
Noninvasive quantiﬁcation of myocardial ﬁbrosis in end-
stage renal disease is challenging. Gadolinium contrast
agents previously used for cardiac magnetic resonance
imaging (MRI) are contraindicated because of an
association with nephrogenic systemic ﬁbrosis. In other
populations, increased myocardial native T1 times on
cardiac MRI have been shown to be a surrogate marker of
myocardial ﬁbrosis. We applied this method to 33 incident
hemodialysis patients and 28 age- and sex-matched
healthy volunteers who underwent MRI at 3.0T. Native T1
relaxation times and feature tracking–derived global
longitudinal strain as potential markers of ﬁbrosis were
compared and associated with cardiac biomarkers. Left
ventricular mass indices were higher in the hemodialysis
than the control group. Global, Septal and midseptal T1
times were all signiﬁcantly higher in the hemodialysis
group (global T1 hemodialysis 1171 ± 27 ms vs. 1154 ± 32
ms; septal T1 hemodialysis 1184 ± 29 ms vs. 1163 ± 30 ms;
and midseptal T1 hemodialysis 1184 ± 34 ms vs. 1161 ± 29
ms). In the hemodialysis group, T1 times correlated with
left ventricular mass indices. Septal T1 times correlated
with troponin and electrocardiogram-corrected QT interval.
The peak global longitudinal strain was signiﬁcantly
reduced in the hemodialysis group (hemodialysis
-17.7±5.3% vs. -21.8±6.2%). For hemodialysis patients, the
peak global longitudinal strain signiﬁcantly correlated with
left ventricular mass indices (R [ 0.426), and a trend was
seen for correlation with galectin-3, a biomarker of cardiac
ﬁbrosis. Thus, cardiac tissue properties of hemodialysis
patients consistent with myocardial ﬁbrosis can be
determined noninvasively and associated with multiple
structural and functional abnormalities.
Kidney International (2016) 90, 845–852; http://dx.doi.org/10.1016/
j.kint.2016.06.014
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P remature cardiovascular disease is the leading cause ofdeath in patients with end-stage renal disease (ESRD).Excessive cardiac mortality is thought to be secondary
to nonatherosclerotic processes, with sudden cardiac death be-
ing a predominant feature.1,2 Left ventricular hypertrophy
(LVH) is common in these patients and is convincingly associ-
ated with cardiovascular and all-cause mortality.3–5 Along with
other risk factors, subclinical ischemia and hemodynamic per-
turbations associated with hemodialysis (HD) are likely to
contribute to the ultimate development of LVH, ventricular
dilation, cardiac dysfunction, and myocardial ﬁbrosis.6–8 The
development of these adverse features reﬂects a cardiomyopa-
thy speciﬁc to uremia that develops early in chronic kidney dis-
ease (CKD).9,10 Detection and ultimately reversal of the
development of this cardiomyopathy are important goals for
improving the morbidity and mortality of CKD patients.
Cardiac magnetic resonance (CMR) imaging is a useful
tool in the detection of cardiac disease. One of the advantages
of CMR imaging is tissue characterization.11 We and others
previously demonstrated myocardial ﬁbrosis in the ESRD
population using contrast-enhanced CMR imaging.9,12 More
recently, imaging and quantifying myocardial ﬁbrosis in
ESRD have been challenging as gadolinium contrast agent use
has been curtailed due to the association between gadolinium
and nephrogenic systemic ﬁbrosis.13 Noncontrast native T1
relaxation time is emerging as a viable alternative to gado-
linium contrast use and has been shown to correlate with
cardiac ﬁbrosis found on tissue histology.14,15 T1 relaxation
time reﬂects the longitudinal recovery time of hydrogen
atoms following their excitation. At any given magnetic ﬁeld
strength, each type of tissue will have its own normal range of
values. Normal cardiac tissue will produce a speciﬁc range of
values; a signiﬁcant departure from the normal range is
thought to represent tissue pathology.16 Increased native T1
time is a surrogate marker of myocardial ﬁbrosis in
other disease states such as amyloidosis and hypertrophic
obstructive cardiomyopathy.17–19
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Although increased myocardial native T1 times have been
demonstrated in early CKD,20 until now the assessment of
native T1 times in ESRD and their comparison with those in a
normal healthy population has not been performed. If T1
times are greater in the ESRD population than in healthy
volunteers, then they warrant further exploration to deter-
mine whether they might also be a marker of cardiac ﬁbrosis
in the renal population. Limiting the evolvement of
myocardial ﬁbrosis could be an exciting and worthwhile
future end point for renal clinical trials.
In this study, we compared native myocardial global and
septal T1 relaxation times as potential markers of diffuse
myocardial ﬁbrosis in incident HD patients with those of
healthy volunteers (HVs). Ejection fraction is often preserved
late into the development of cardiomyopathy.21 Myocardial
strain is a more useful early marker of abnormal cardiac
muscle structure and function as myocardial tissue compli-
ance will in theory be reduced with increasing ﬁbrosis. As
echocardiographic global longitudinal strain (GLS) is pre-
dictive of histologic ﬁndings of uremic cardiomyopathy and
ﬁbrosis in rat CKD models22 as well as being independently
predictive of increased mortality,23 we also compared feature-
tracking CMR imaging–derived GLS between groups.
In the incident HD group, we examined the relationship be-
tween these variables and an emerging blood biomarker, galectin-
3,which is potentially a surrogate ofmyocardialﬁbrosis.24Wealso
assessed the relationship between 12-lead electrocardiographic
abnormalities, CMR imaging–derived cardiac indices, and other
laboratory parameters including the more traditional markers of
increased cardiac risk—N-terminal b-natriuretic peptide 1 (NT-
proBNP) and highly sensitive troponin T (hs-tropT).
RESULTS
Participants
A total of 61 aged- and sex-matched subjects were enrolled:
28 HVs and 33 HD patients. Baseline demographic charac-
teristics of the HD population and the prevalence of tradi-
tional cardiovascular risk factors in this group are shown in
Table 1. The HVs had no cardiovascular or systemic disease
and had a normal electrocardiogram. They were not treated
for hypertension or hypercholesterolemia and were taking no
regular medications. Table 2 lists prescribed medication use
by the HD patients (Table 2).
Left ventricular mass and function
Left ventricular (LV) mass was signiﬁcantly greater in the HD
group: the median LV mass indexed to body surface area
(LVMI) in the HD group was 69.8 g/m2 (interquartile range,
61.3–88) versus the HV group (55.0 g/m2) (interquartile
range, 50.7–62.2) (P < 0.001). One participant in the HV
group had LVH (deﬁned as an LVMI >84.1 g/m2 for male
participants and >76.4 g/m2 for female participants).25 In the
HD group, 14 participants (42.4% of all HD participants) had
LVH (P ¼ 0.001).
LV ejection fraction was similar between the groups
(Table 3). Five participants (15.2%) in the HD group
had LV systolic dysfunction, deﬁned as an LV ejection
fraction <55%)25 compared with no participants in the HV
group (P ¼ 0.056). LV end-diastolic volumes and end-systolic
volumes were similar between the groups. Full cardiac pa-
rameters of both groups are detailed in Table 3.
Table 1 | Baseline Demographic Characteristics and Clinical
Data for HD Patients
Variable
All HD Patients
(N [ 33)
Primary renal diagnosis (%)
Diabetic nephropathy 24.2 [8]
Polycystic kidney disease 15.2 [5]
Renovascular disease 12.1 [4]
Glomerulonephritis 24.2 [8]
Unknown cause 12.1 [4]
Other known 12.1 [4]
Length of time on HD (mo) 5.5  2.7
Mean UF volume (l) 1.7  1.0
Dialysis access (%)
Fistula 81.8 [27]
Graft 3 [1]
Tunneled line 15.2 [5]
Diabetes [%] 24.2 [8]
Hypertension [%] 60.6 [20]
Myocardial infarction [%] 12.1 [4]
Ischemic heart disease [%] 18.2 [6]
Stroke [%] 15.2 [5]
Peripheral vascular disease [%] 9.1 [3]
Systolic blood pressure (mm Hg) 138 (131–155)
Diastolic blood pressure (mm Hg) 78 (67–83)
Hemoglobin (mg/dl) 111 (103–118)
Urea reduction ratio (%) 73 (68–78)
Albumin (g/l) 35 (32–36)
C-reactive protein (mmol/l) 8 (3–14)
Phosphate (mmol/l) 1.73 (1.33–2.18)
Corrected calcium (mmol/l) 2.35 (2.24–2.39)
Parathyroid hormone (mmol/l) 48.1 (24.5–85.9)
Galectin-3 (ng/ml) 17.5 (13.4–22.0)
hs-Troponin Ta (pg/ml) 33.7 (23.5–46.9)
NT-BNPa (pg/ml) 1934 (1111–5111.5)
ECG QTcb (m/s) 435 (412.8–453)
ECG, electrocardiogram; HD, hemodialysis; hs-Troponin T, highly sensitive Troponin
T; NT-proBNP, N-terminal b-natriuretic peptide 1; UF, ultraﬁltration.
All data presented as percentage [number of participants], median (interquartile
range), or mean  SD, as appropriate.
ahs-Troponin T and NT-BNP values were available for 31 HD participants.
bQTc was available for 28 HD participants.
Table 2 | Prescribed Medications in the HD Participants
Medication
HD Participants Taking
(N [ 33)
Erythropoietin 78.8 (26)
Beta-blocker 57.6 (19)
Aspirin 24.2 (8)
Clopidogrel 24.2 (8)
ACE inhibitor 9.1 (3)
Diuretics 27.3 (9)
Calcium channel blockers 39.4 (13)
Alpha-blockers 6.1 (2)
Statin 54.5 (18)
ACE, angiotensin-converting enzyme; HD, hemodialysis.
Data shown as percentage (number of participants).
c l i n i ca l i nves t iga t i on E Rutherford et al.: T1 mapping in end-stage renal disease
846 Kidney International (2016) 90, 845–852
Native T1 times
Global T1 time and septal and midseptal T1 times were greater
in the HD group compared with the HV group (Table 3):
global T1 time in the HD group, 1171  27 ms versus the HV
group, 1154  32 ms, P ¼ 0.025; septal T1 time in the HD
group, 1184  29 ms versus the HV group, 1163  30 ms,
P ¼ 0.007 (Figure 1); midseptal T1 time in the HD group,
1184  34 ms versus the HV group, 1161  29 ms, P ¼ 0.006.
Correlation of myocardial native T1 times (in milliseconds)
with LV mass indices and function
In the HD group, LVMI correlated consistently with all
measures of T1 times: Pearson’s R for global T1 with
an LVMI ¼ 0.452 (P ¼ 0.008), for septal T1 with an
LVMI ¼ 0.449 (P ¼ 0.009) (Figure 2), for midseptal T1 with
an LVMI ¼ 0.498 (P ¼ 0.003). Septal T1 times positively
correlated with end-diastolic volumes: Pearson’s R for global
T1 ¼ 0.323, P ¼ 0.067, for septal T1 ¼ 0.380 (P ¼ 0.029), for
midseptal T1 ¼ 0.462 (P ¼ 0.007). T1 times did not relate to
ejection fraction.
Feature tracking–derived strain
Peak GLS was reduced in the HD group compared with the
HV group (HD group: GLS, 17.7  5.3% vs. HV
group, 21.8  6.2%, P ¼ 0.008).
In the HD group, GLS correlated with LVMI (Spearman’s
R ¼ 0.426, P ¼ 0.013) and negatively correlated with ejection
fraction (Pearson’s R ¼ 0.535, P ¼ 0.001). In the HD group,
GLS also correlated with increasing end-systolic volume
(Spearman’s R ¼ 0.440, P ¼ 0.01), which is associated with a
poorer prognosis in HD.26
Unlike a previous study of early CKD using feature
tracking–derived strain methods,20 we found no difference in
early diastolic strain rate or strain rate between the HD and
HV groups. There was no correlation between any marker of
strain and native T1 values.
Relationship of CMR imaging ﬁndings to hs-tropT, NT-
proBNP, and galectin-3
In the HD group, LVMI correlated with NT-proBNP
(Spearman’s R ¼ 0.365, P ¼ 0.044). LVMI did not correlate
with hs-tropT or galectin-3. Septal T1 correlated with pre-
dialysis hs-tropT (Spearman’s R ¼ 0.397, P ¼ 0.027) but not
with NT-proBNP or galectin-3. GLS showed a trend toward
correlation with galectin-3 (Spearman’s R ¼ 0.344, P ¼ 0.05).
There was no correlation between GLS and NT-proBNP or
hs-tropT.
Table 3 | Patient Characteristics and Cardiac Parameters of HV
and HD Patients
Variable
Healthy Volunteers
(N [ 28)
HD Patients
(N [ 33) P Value
Age (yr) 60 (53.8–72.3) 56 (50–71) 0.562
Male [%] 57.1 [16] 57.6 [19] 0.973
Weight (kg) 79 (68.8–89) 73.9 (63–83) 0.343
BMI (kg/m2) 25.6 (24.1–29.5) 27.7 (23.1–30.5) 0.772
Ethnicity
White 96.4 [27] 90.9 [30] 0.618
South Asian 3.6 [1] 9.1 [3] 0.618
Global T1 (ms) 1154  32 1171 27 0.025
Septal T1 (ms) 1163  30 1184  29 0.007
Midseptal T1 (ms) 1161  29 1184  34 0.006
LVM (g) 107.7 (89.9–115.6) 131.7 (105.8–152.6) 0.001
LVMI (g/m2) 55.0 (50.7–62.2) 69.8 (61.3–88) 0.001
LVH (%) 3.6 [1] 42.4 [14] 0.001
EDV (ml) 148.4 (128.2–168.9) 142.9 (133.6–163.8) 0.856
EDVI (ml/m2) 77.4  9.7 83.8  23.4 0.180
ESV (ml) 56.8 (43.4–62.4) 51.2 (41.8–64.1) 0.783
ESVI (ml/m2) 28.4  6.0 32.0  17.5 0.307
LV Dilation 0 [0] 9.1 [3] 0.243
Stroke Volume (ml) 94.4 (75.8–103.4) 92.8 (74.2–112.2) 0.954
Ejection Fraction (%) 63.3  5.2 63.2  9.3 0.963
LVSD (%) 0 [0] 15.2 [5] 0.056
GLS (%) -21.8  6.2 -17.7  5.3 0.007
Strain Rate (s1) 1.06  0.37 0.95  0.24 0.140
EDSR (s-1) 0.97  0.36 1.03  0.36 0.473
BMI, body mass index; EDSR, early diastolic strain rate; EDV, end-diastolic volume;
EDVI, end-diastolic volume indexed to body surface area; ESV, end-systolic volume;
ESVI, end-systolic volume indexed to body surface area; GLS, global longitudinal
strain; HD, hemodialysis; HV, health volunteer; LV dilation, left ventricular dilation;
LVH, left ventricular hypertrophy; LVM, left ventricular mass; LVMI, left ventricular
mass indexed to body surface area; LVSD, left ventricular systolic dysfunction.
All data are shown as mean  SD, median (interquartile range), or percentage
[number of participants], as appropriate.
Figure 1 | Boxplot comparing septal T1 times in healthy
volunteers and hemodialysis (HD) patients.
Figure 2 | Scatterplot of septal T1 times against left ventricular
mass indexed to body surface area (LVMI) in hemodialysis
patients. g m-2, grams per meter squared.
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12-Lead electrocardiogram and CMR imaging ﬁndings
Twenty-eight (85%) HD participants had a pre-HD electro-
cardiogram available for analysis, and 27 of these subjects
(96.4%) were in sinus rhythm. One participant had right
bundle branch block. The median corrected QT interval was
435 ms. Signiﬁcantly, there were interrelations of the Q-T
interval time (QTc) with septal T1 (Spearman’s R ¼ 0.376,
P ¼ 0.045) and NT-proBNP (Spearman’s R ¼ 0.472,
P ¼ 0.011). There were no demonstrated relationships be-
tween LVMI or strain and QTc.
Relationship of interdialytic ﬂuid gains and ultraﬁltration
volumes with CMR imaging ﬁndings
The weight difference between the “dry weight” at the end of
dialysis the day before imaging and the weight at the time of
scanning correlated with LVM (but not LVMI) (Spearman’s
R ¼ 0.384, P ¼ 0.027). There was no correlation between T1
times and this postdialysis weight gain (global T1 and prescan
weight change: Spearman’s R ¼ 0.052, P ¼ 0.776). Strain also
was not related to this weight change. An average of partici-
pants’ HD ultraﬁltration volumes for the 30 days before im-
aging correlated with LVM, but not LVMI (Spearman’s
R ¼ 0.422 P ¼ 0.015). There was no relationship between
any measure of T1 time and 30-day mean ultraﬁltration
(global T1 and mean ultraﬁltration Spearman’s R ¼ 0.114,
P ¼ 0.529). There was no correlation demonstrated between
any measure of strain and ultraﬁltration volumes.
Inﬂuence of blood pressure and dialysis adequacy on CMR
imaging ﬁndings
In the HD group LVM (but not LVMI) correlated with dia-
stolic blood pressure, correlation of LVM with systolic BP did
not reach statistical signiﬁcance (systolic blood pressure:
Spearman’s R ¼ 0.334, P ¼ 0.057; diastolic blood pressure:
R ¼ 0.403, P ¼ 0.02). There was no correlation demonstrated
between global, septal, or midseptal T1 times or strain
and blood pressure. There was a negative correlation
between dialysis urea reduction ratio and LVMI (Pearson’s
R ¼ 0.560, P ¼ 0.001). Further supporting the implication
that HD adequacy was strongly correlated with LVMI, there
were correlations between adjusted calcium and phosphate
values and LVMI (calcium: Spearman’s R ¼ 0.462, P ¼
0.007; phosphate: Pearson’s R ¼ 0.358, P ¼ 0.041).
T1 times did not relate to the urea reduction ratio. GLS
negatively correlated with dialysis urea reduction ratios
(Spearman’s R ¼ 0.348, P ¼ 0.047). T1 times and strain
were not related to calcium or phosphate.
Relationship of other factors known to contribute to LVH in
ESRD to CMR imaging ﬁndings
HD patients with anemia (deﬁned as hemoglobin <100 mg/
dl) had a higher LVMI than those without. The median LVMI
in the 6 anemic HD patients was 92.1 g/m2 compared with
65.7 g/m2 in those with a hemoglobin $100 mg/dl
(P ¼ 0.008). Our study was not powered to detect a potential
small difference in T1 times in anemic patients. Median
global T1 time in patients with anemia was 1190 ms (IQR,
1164.9–1209.9) versus 1171 ms (IQR, 1150.9–1187.1) (P ¼
0.189). GLS was reduced in anemic patients: GLS:
anemia ¼ 13.5  3.9% versus 18.6  5.1% (P ¼ 0.025).
Of the HD participants, 81.8% were receiving dialysis
through an arteriovenous ﬁstula. There was no demonstrated
difference in LVMI, strain, or T1 times across different types
of dialysis access. No correlation was seen between age or
dialysis vintage and LVMI, strain, or T1 time; 24.2% of par-
ticipants were diabetic. There was no statistical difference in
LVMI, any T1 measurements, or strain between those HD
participants with and without diabetes.
T1 image quality and reproducibility
Of a total 976 T1 regions of interest (Figure 3), 808 (82.8%)
were considered suitable for analysis. The greatest reliability
of measurement was seen for septal T1 measurement. Septal
T1 segments were less affected by artifact than other seg-
ments. The intraclass correlation coefﬁcient for reliability of
global T1 measurement was 0.872 (95% conﬁdence interval
0.630–0.914, P < 0.001); for septal T1, it was 0.941 (95% CI
0.871–0.974, P < 0.001); and for midseptal T1, it was 0.901
(95% CI 0.786–0.955, P < 0.001).
DISCUSSION
This study is the ﬁrst to compare native T1 times in HD
participants with those of HVs. We demonstrated that T1
times are signiﬁcantly prolonged in the HD population and
correlate with increased LVMI. The increased T1 times
demonstrated in the HD population may be representative of
the cardiac ﬁbrosis known to be found in ESRD. Native T1
mapping might be a novel way to quantify cardiac tissue
abnormalities in HD. T1 times could be further investigated
as a future surrogate end point in renal clinical trials. The
utility of T1 times is further evidenced by their association
with LVMI, suggesting that as LVH progresses in severity, the
Figure 3 | A typically segmented T1 map of a basal myocardial
slice in a hemodialysis patient. Min/Max, minimum/maximum.
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underlying tissue abnormalities that lead to longer T1 times
increase in parallel. Although it is our assertion that these
prolonged T1 times might be representative of myocardial
ﬁbrosis, without a tissue diagnosis, this cannot be proved. It
should be noted that in our study that the proportion of LVH
was lower than in some other HD studies. These were HD
patients with a short dialysis vintage with a mean duration of
renal replacement therapy of 5.5 months.
Rationale for global and septal T1 analysis
The majority of previous studies considering native T1 times
in other populations (as well as a single study in early CKD)20
consider increased septal T1 times to be representative of a
diffuse ﬁbrotic process. In most populations, it is possible to
verify this through correlation with diffuse ﬁbrosis seen after
gadolinium contrast administration. As routine gadolinium-
based contrast agent use has been curtailed in the ESRD
population, veriﬁcation of this assumption by this method is
not practical. Additionally, although the correlation of native
septal T1 times with diffuse cardiac ﬁbrosis has also been
borne out by cardiac tissue biopsy in several populations14,15
and a previous LV biopsy study conﬁrmed histologic evidence
of diffuse ﬁbrosis in ESRD,27 no study relating native septal
T1 time in ESRD to cardiac tissue histology has ever
been performed.
Therefore, in order to ensure that we did not falsely as-
sume that a localized high septal T1 time was representative of
a diffuse process, we measured T1 times throughout 3 short-
axis slices: basal, mid, and apical. Using the 16-segment
model of the American Heart Association,28 we calculated
an average global T1 time from all 16 regions of interest.
Using this method, we were able to demonstrate that truly
global T1 times were higher in the HD population than in
healthy controls. Global T1 times were very closely correlated
with septal T1 times (Pearson’s R ¼ 0.885, P < 0.001). We
analyzed midseptal T1 times alone on the assumption that the
apical short-axis slice might be more susceptible to motion
artifact than the midslice; however, midseptal T1 times were
not of any greater value than septal T1 time. Furthermore,
using only 2 segments to calculate midseptal T1 increases the
risk of regional ischemia inﬂuencing results.
Inﬂuence of traditional ischemic heart disease on T1 times
Native T1 times are known to be locally higher in areas of
cardiac injury, for example, after a chronic myocardial
infarction.29 Our HD population was unselected, and a pro-
portion of patients had known ischemic heart disease. Before
any knowledge of the association of gadolinium contrast use
and nephrogenic systemic ﬁbrosis in ESRD, it was described
using gadolinium contrast that there are 2 patterns of cardiac
ﬁbrosis seen in ESRD: that of the traditional ischemic heart
disease with subendocardial ﬁbrosis and that of a more
diffuse uremic cardiomyopathy.9,12 We do not believe that the
prolonged T1 times in the HD group were a consequence
of traditional ischemic heart disease. Four HD partici-
pants had a history of myocardial infarction. Two observers
independently reviewed cine images of these participants to
exclude any patients who had thinned akinetic myocardial
segments, which is commonly accepted as a surrogate of
transmural chronic myocardial infarction. The observers
agreed that there was no evidence of myocardial wall thinning
on any of their images. Furthermore, if these 4 participants
were excluded entirely, then the average global, septal, and
midseptal T1 times for the HD group were essentially unal-
tered (global T1 with myocardial infarction patients
excluded ¼ 1170  27 ms vs. 1171  27 ms with myocardial
infarction patients included).
Arrhythmia, hs-tropT, and T1 time
Interestingly, we saw a relationship between septal T1 and
predialysis hs-tropT. Septal times also related to QTc.
Increased corrected Q-T interval times are associated with an
increased risk of sudden cardiac death.30 The increased inci-
dence of sudden cardiac death is a poorly understood phe-
nomenon in ESRD that cannot be entirely attributed to
electrolyte disturbances.30 A study in rats showed that rats
with induced CKD develop both LVH and increased suscep-
tibility to arrhythmia.31 In this study, there were also some
early signs that cardiac ﬁbrosis began to develop in the rats.
The demonstrated correlation between septal T1 times and
troponin T and septal times and QTc in our study warrants
further exploration.
GLS, ejection fraction, and early myocardial dysfunction
Our study showed no difference in ejection fraction between
HV and HD groups. It is well-known that ejection fraction is
often preserved until late in the development of cardiomy-
opathy, and thus it is not a reliable primary end point for
renal clinical trials.21 Recent studies showed that echocar-
diographic myocardial strain is an independent predictor of
increased mortality in CKD populations.22,23
In this study, there was a trend toward a correlation of GLS
with galectin-3 (Spearman’s R ¼ 0.344, P ¼ 0.05). Given our
small sample size, we consider this result to be of some in-
terest. Galectin-3 is an established biomarker of myocardial
ﬁbrosis. The trend identiﬁed makes sense as GLS measured by
speckle tracking echocardiography is predictive of histologic
ﬁndings of uremic cardiomyopathy and cardiac ﬁbrosis in rats
with CKD.22
Assessment of GLS using speckle tracking echocardiogra-
phy is recommended in recent guidelines for the quantitative
assessment of LV function.32 However, echocardiography is
not an ideal tool for clinical trials in ESRD because dialysis-
associated ﬂuid shifts can lead to overestimation of ventric-
ular indices and variations in assessment of cardiac func-
tion.33 Use of a single imaging modality to assess outcomes in
the HD population is preferable, and we consider CMR im-
aging to be the modality of choice. In particular because,
more recently, myocardial strain quantiﬁed by CMR imaging
has been found to be associated with adverse outcomes.34
Although there was no correlation of T1 times with GLS,
our ﬁndings of a difference in GLS between the HD and HV
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groups, as well as the correlation of GLS with LVM in HD,
support the assertion that altered myocardial strain me-
chanics have some role in the process of development of LVH
and potentially ﬁbrosis in CKD patients. Whether abnormal
GLS is a cause or a consequence of cardiomyopathy devel-
opment needs to be further investigated. Similarly, the lack of
a correlation of T1 times with GLS in this study should be
considered further. At present, it is not clear whether our
study was underpowered to detect a relationship between the
2 or whether they reﬂect slightly different aspects of patho-
logic processes in the heart. In any case, they both have their
own merits; GLS is a dynamic measure, whereas T1 time is
arguably a more ﬁxed quantity.
Limitations
Although our study numbers are relatively small and all
participants came from a single center, we have been able to
present a well-characterized group of dialysis patients with a
short dialysis vintage. The incidence of diabetes in our study
population (24.2%) was less than that in many typical HD
populations, and our study population was not racially
diverse. We were unable to perform multivariable adjust-
ments to assess for independence of any of our ﬁndings.
Our study would have been strengthened by the addition
of a control population of hypertensive patients with LVH and
without renal disease. However, there is some evidence from
other studies that included a control group that in contrast to
LVMI, T1 times are independent of blood pressure.20 The fact
that T1 times and strain were not related to blood pressure in
our study provides some further reassurance in this regard.
Without biopsy conﬁrmation, we cannot be certain that
the cardiac abnormalities identiﬁed in this population are
representative of ﬁbrosis. It is recognized that water content
can prolong T1 times, and this is undoubtedly a limitation of
our study as we cannot be sure of the precise inﬂuence of this
on our results.35 However, we saw no correlation with weight
gain between HD and imaging with T1 times. Similarly, there
was no correlation between T1 time and ultraﬁltration vol-
umes. Both of these markers, which are representative of
changing ﬂuid status, correlated with LVM. Overall, we
believe that these ﬁndings support our assertion that
increased T1 times in the HD population are likely to reﬂect
tissue abnormalities (potentially ﬁbrosis). Previous biopsies of
the uremic hearts have shown extensive myocardial ﬁbrosis,
which would be consistent with our conclusions.27
Implications of our study ﬁndings
T1 times are a potentially novel way to quantify cardiac tissue
abnormalities in ESRD. In the future, they may be conclu-
sively demonstrated to be a surrogate marker of ﬁbrosis.
Nephrologists should note that normal values will vary from
scanner to scanner. The next steps for development of T1
mapping as a widely applicable clinical tool will involve each
center developing robust normal values for each of their
scanners. Phantom work will be required before any future
multicenter collaborations run successfully.
We showed that T1 times are abnormally high in the HD
population. Perhaps in the future, change in T1 times could
potentially be a primary outcome measure in renal clinical
trials. However, a number of questions need to be answered
before this can happen: what is the natural history of T1 times
throughout the progression of CKD, do T1 times change after
renal transplantation, how exactly are T1 times affected by
ﬂuid status variation, and are increased T1 times associated
with increased risk of future cardiovascular events and mor-
tality. To date, increased T1 times have been shown to be
predictive of mortality in amyloidosis36; the utility of T1 times
to predict mortality in other populations remains to be
proved.
METHODS
Participants
Sixty-one participants were included in the study. All participants
were older than 18 years of age and had no contraindications to
CMR scanning. HD participants were eligible if they had
commenced dialysis within the past 12 months; baseline scans for all
eligible patients in 2 concurrent studies recruiting in Glasgow were
used. In total, 33 HD patients were recruited from the Cardiac
Uraemic ﬁbrosis Detection in DiaLysis patiEnts study (CUDDLE
study, ISRCTN99591655), and the ALTERED study (Does ALlopu-
rinol Regress LefT Ventricular Hypertrophy in End Stage REnal
Disease, NCT01951404). A total of 28 age- and sex-matched healthy
volunteers were recruited from a Glasgow-based study examining
variations in native T1 relaxation times in healthy adults.37 Healthy
volunteers within 5 years of age of each HD participant were blindly
selected from a list of HV participants that detailed only the HV
participants’ age and sex.
All participants provided written informed consent, and all
studies were approved by local ethics committees (CUDDLE: West of
Scotland Research Ethics Service, reference 13/WS/0301, healthy
volunteers: 11/AL/0190; ALTERED: East of Scotland Research Ethics
Service, 13/ES/0051).
Inclusion and exclusion criteria
The HV group had no cardiovascular or systemic disease and had
normal electrocardiograms. They were not treated for hypertension
or hypercholesterolemia and were taking no regular medications.
HD patients were excluded if they had atrial ﬁbrillation (as this
makes magnetic resonance imaging and electrocardiographic gating
difﬁcult). All HD patients had been receiving renal replacement
therapy for less than 1 year. ALTERED patients were not taking
allopurinol, had a life expectancy >1 year, and did not have
echocardiogram-deﬁned LV systolic dysfunction.
Magnetic resonance image acquisition
All participants underwent 3-T CMR imaging (MAGNETOM Verio,
Siemens Healthcare, Erlangen, Germany) at the British Heart
Foundation Clinical Research Centre, University of Glasgow. In the
HD patients, CMR imaging was consistently performed on a post-
dialysis day. Baseline ALTERED study magnetic resonance imaging
scans were used before any study intervention. A double radio-
frequency coil array (anterior and posterior) was used. The scans
were electrocardiographically gated. The imaging protocol included
cine magnetic resonance with steady-state free precession and T1
mapping sequences.35 The full left ventricle was captured in a cine
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short-axis stack. Cine acquisition parameters included 41.4-ms
repetition time, 40 ﬂip angle, 1.51-ms echo time, 256  173-pixel
matrix, 1.5  1.3  8-mm voxel size, 8-mm slice thickness, and
977-Hz/pixel bandwidth.
Basal, mid, and apical T1 maps were acquired in 3 short-axis
slices using a motion-corrected, optimized, modiﬁed Look-Locker
inversion recovery investigational prototype sequence without
contrast administration (Siemens Healthcare, works-in-progress
method 448). T1 imaging parameters included 267.84-ms repeti-
tion time, 35 ﬂip angle, 1.06-ms echo time, 100-ms T1 of the ﬁrst
experiment, 80-ms T1 increment, 124  192 pixel matrix, 2.2 
1.8  8.0-mm spatial resolution, 930-Hz/pixel bandwidth, and
17-heartbeat (range, 12–18 s) scan time.
Image analysis
LVM and function. A single observer analyzed anonymized
images in a random order to determine cardiac indices including
LVM and function by manually tracing endocardial and epicardial
borders at end-systole and end-diastole on the short-axis cine images
as according to well-established protocols.37 End-systolic and end-
diastolic volumes and LVM were calculated and indexed to body
surface area (using a weight acquired immediately prescan) using the
Siemens Argus analysis software.
T1 maps. On the raw T1 images, LV contours were deﬁned and
copied onto the color-enhanced spatially coregistered maps. Using
the anterior right ventricular-LV insertion post as a reference, T1
maps were segmented according to the American Heart Association
16-segment model.28 Segmental American Heart Association regions
of interest were delineated by user-deﬁned semiautomated border
delineation (Siemens Argus analysis software). The regions of in-
terest were standardized to be of similar size and shape. T1 times
were measured in each of the 16 segments, with care taken to
delineate regions of interest with adequate margins of separation
from tissue interfaces such as between the blood pool and myocar-
dium. A typical T1 map is shown in Figure 3.
Each individual segment was assessed for the presence or absence
of susceptibility and motion artifacts. After removal of any segments
affected by artifact, a global T1 time was calculated from the mean of
all remaining segments. A septal T1 time was calculated by averaging
the acceptable anteroseptal, inferoseptal, and septal American Heart
Association segments (segment numbers 2, 3, 8, 9, and 14). Mid-
septal T1 time was derived from an average of included septal seg-
ments from the midshort-axis slice (segment numbers 8 and 9). T1
map reproducibility was assessed by blinded reanalysis of 25
randomly selected images by the same observer.
Strain. Dedicated feature-tracking software (Diogenes Image
Arena, Munich, Germany) was used on the horizontal long-axis cine
acquisition. In a method previously described,38,39 the end-diastolic
frame was identiﬁed for each image, and endocardial borders were
delineated. The delineated contour was then automatically propa-
gated throughout the cardiac cycle. GLS, strain rate, and early dia-
stolic strain rate were then calculated. Intraobserver reproducibility
was checked by blinded reanalysis of a proportion of images
(n ¼ 20).
12-Lead electrocardiograms
In the HD group, predialysis 12-lead electrocardiograms were ob-
tained for 28 participants. The underlying rhythm was recorded.
Corrected QTc was noted from the electronic print out of each
electrocardiogram.
HD patient biomarkers and other clinical parameters
Frozen stored predialysis blood samples were obtained in the HD
group for analysis of hs-tropT, NT-proBNP (e411, Roche Di-
agnostics, Burgess Hill, UK), and galectin-3 (Bio-Techne, Abingdon,
UK). All were analyzed using the manufacturer-recommended pro-
tocols and calibrations. Available collected blood tests from the time
of imaging, including hemoglobin, urea reduction ratios, albumin,
C-reactive protein, phosphate, parathyroid hormone, glucose, pre-
dialysis creatinine and potassium, lipid proﬁle, as well as each HD
participant’s medical and dialysis history including ultraﬁltration
volumes and postdialysis weights were obtained from electronic
records.
Statistics
All statistical analyses were performed using SPSS version 22
(Armonk, NY) and STATA 13 (StataCorp, College Station, TX).
Paired t tests (for parametric data) and Mann-Whitney U tests (for
nonparametric data) were used to compare continuous indices be-
tween HVs and HD patients. Categorical data were assessed using the
c2 test or the Fisher exact test, as appropriate. Correlations within
each group between continuous indices were assessed using Pearson’s
and Spearman’s correlation coefﬁcients for parametric and
nonparametric data, respectively.
At the time of the start of this study, there were few data to
inform a power calculation using native T1 times at 3-T CMR im-
aging. Based on our normal volunteer study,37 to detect a 30-ms
difference in mean native T1 time between a group of HVs and
patients with ESRD, at 90% power and a probability of a type 1 error
of 0.05 would require 22 per group, based on a standard deviation in
T1 time of 30 ms in each group.
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